Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Impact of COVID-19 on CLL treatment in Italy

Antonio Cuneo • 23 Sep 2020
SOHO Italy 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

Antonio Cuneo, MD, PhD, University of Ferrara, Ferrara, Italy, outlines the impact of the COVID-19 pandemic on the treatment of chronic lymphocytic leukemia (CLL) in Italy, and outlines the risk of COVID-19 high-risk disease in patients with CLL. Dr Cuneo also discusses the use of the BTK inhibitor ibrutunib, which may show efficacy against the COVID-19 pandemic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Antonio Cuneo

2:18
Tools to improve the outcomes of patients with CLL affected by COVID-19
Antonio Cuneo • 7 Oct 2022
1:25
The management of CLL in Italy
Antonio Cuneo • 7 Oct 2022
1:09
The impact of complex karyotype on treatment efficacy and prognosis in CLL
Antonio Cuneo • 7 Oct 2022
1:45
The importance of real-world data in CLL & efficacy of BTK and Bcl-2 inhibitors in the real world
Antonio Cuneo • 7 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals